According to the American Academy of Dermatology, more than half of chronic itch cases without visible rash may involve an ...
EMERALD-3: Phase III trial of IMFINZI ® (durvalumab) in combination with IMJUDO ® (tremelimumab-actl), with or without lenvatinib, and transarterial chemoembolization (TACE) in patients with ...